Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04788576
Other study ID # HFpEF_CMD
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 25, 2021
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source Samsung Medical Center
Contact Ki Hong Choi, MD
Phone 82-2-3410-1246
Email cardiokh@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the incidence of coronary microvascular dysfunction (CMD) and its' prognostic implication in patients who have diagnosed as heart failure with preserved ejection fraction (HFpEF) confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease.


Description:

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in patients with current or prior symptoms of HF with a left ventricular ejection fraction (LVEF) ≥ 50 percent and evidence of cardiac dysfunction as a cause of symptoms (abnormal LV filling and elevated filling pressures). Previous studies have reported that HFpEF is related to various clinical risk factors such as hypertension, obesity, diabetes mellitus, chronic kidney disease, atrial fibrillation, myocardial ischemia with or without significant epicardial coronary artery stenosis, or myocardial infiltrative disease. Although its pathophysiology remains incompletely understood, findings from clinical and pre-clinical studies have suggested systemic endothelial dysfunction, oxidative stress, and coronary microvascular dysfunction (CMD) could be important pathophysiologic mechanisms for HFpEF. In this regard, recent studies evaluated non-invasively measured coronary flow reserve (CFR) from positron emission tomography (PET), cardiac magnetic resonance imaging (MRI), or Doppler echocardiography, and presented the association of depressed global CFR with cardiac diastolic dysfunction and higher risk of clinical events. The presence of CMD can be also evaluated by invasive physiologic assessment using both CFR and index of microcirculatory resistance (IMR). Nevertheless, there has been limited study which evaluated the association between HFpEF and CMD using invasive physiologic indices and their prognostic implications, especially in patients without significant coronary artery stenosis. Therefore, we sought to evaluate the incidence of CMD and its' prognostic implication in patients who have diagnosed as heart failure with preserved ejection fraction (HFpEF) confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Subject must be at least 19 years of age. - Subject with preserved ejection fraction (ejection fraction > 50%) - Subject presented with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF =5 or 2-4 with abnormal stress test or invasive hemodynamic test) - Subject who clinically need coronary angiography - Subject who is able to voluntarily sign informed consent form Exclusion Criteria: - Subject with reduced ejection fraction (<50%) - Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis =90% or 50-90% with fractional flow reserve [FFR] =0.80) - Subject who has other obvious causes of dyspnea (ex, lung disease) - Subject who have non-cardiac co-morbid conditions with life expectancy <1 year

Study Design


Related Conditions & MeSH terms

  • Coronary Microvascular Dysfunction
  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction

Intervention

Diagnostic Test:
Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)
In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of CMD in patients with HFpEF Proportion of CMD confirmed by invasive physiologic evaluation Immediate after the index procedure
Secondary Correlation between CMD and left ventricular end diastolic pressure Correlation between CMD confirmed by invasive physiologic evaluation and left ventricular end diastolic pressure Immediate after the index procedure
Secondary Correlation between CMD and E/e' Correlation between CMD confirmed by invasive physiologic evaluation and E/e' Immediate after the index procedure
Secondary Correlation between CMD and HFA-PEFF score Correlation between CMD confirmed by invasive physiologic evaluation and HFA-PEFF score Immediate after the index procedure
Secondary Correlation between CMD and NT-proBNP Correlation between CMD confirmed by invasive physiologic evaluation and NT-proBNP Immediate after the index procedure
Secondary Correlation between CMD and pulmonary artery wedge pressure Correlation between CMD confirmed by invasive physiologic evaluation and pulmonary artery wedge pressure Immediate after the index procedure
Secondary Correlation between CMD and mean pulmonary artery pressure Correlation between CMD confirmed by invasive physiologic evaluation and mean pulmonary artery pressure Immediate after the index procedure
Secondary All-cause death All-cause death during follow-up At 2 years after the index procedure
Secondary Cardiac death Cardiac death during follow-up At 2 years after the index procedure
Secondary Myocardial infarction Myocardial infarction during follow-up At 2 years after the index procedure
Secondary Any revascularization Any revascularization during follow-up At 2 years after the index procedure
Secondary Readmission due to heart failure Readmission due to heart failure during follow-up At 2 years after the index procedure
Secondary Readmission Readmission during follow-up At 2 years after the index procedure
Secondary Proportion of heart failure with reduced ejection fraction Proportion of progression of heart failure with reduced ejection fraction At 2 years after the index procedure
Secondary Correlation between CMD and Excercise induced E/e' Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced E/e' Immediate after the index procedure
Secondary Correlation between CMD and Exercise induced pulmonary artery wedge pressure Correlation between CMD confirmed by invasive physiologic evaluation exercise induced and pulmonary artery wedge pressure Immediate after the index procedure
Secondary Correlation between CMD and exercise time Correlation between CMD confirmed by invasive physiologic evaluation exercise time Immediate after the index procedure
Secondary Correlation between CMD and mean exercise induced pulmonary artery pressure Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced mean pulmonary artery pressure Immediate after the index procedure
Secondary Correlation between CMD and Gas analysis data (Peak exercise oxygen consumption, Respiratory quotient) Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced peak exercise oxygen consumption, Respiratory quotient Immediate after the index procedure
See also
  Status Clinical Trial Phase
Suspended NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT06379152 - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1